Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report
Introduction. Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD). With the ageing of population, the frequency of PD is expected to increase dramatically in the coming decades. L-DOPA (1,3,4-dihydroxyalanine) is the most effective drug in the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2020/2671070 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553291202953216 |
|---|---|
| author | Shiro Mawatari Shinji Ohara Yoshihide Taniwaki Yoshio Tsuboi Toru Maruyama Takehiko Fujino |
| author_facet | Shiro Mawatari Shinji Ohara Yoshihide Taniwaki Yoshio Tsuboi Toru Maruyama Takehiko Fujino |
| author_sort | Shiro Mawatari |
| collection | DOAJ |
| description | Introduction. Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD). With the ageing of population, the frequency of PD is expected to increase dramatically in the coming decades. L-DOPA (1,3,4-dihydroxyalanine) is the most effective drug in the symptomatic treatment of PD. Nonmotor symptoms in PD include sleep problems, depression, and dementia, which are not adequately controlled with dopaminergic therapy. Here, we report the efficacy of oral administration of scallop-derived ether phospholipids to some nonmotor symptoms of PD. Methods. Ten (10) patients received oral administration of 1 mg/day of purified ether phospholipids derived from scallop for 24 weeks. Clinical symptoms and blood tests were checked at 0, 4, 12, 24, and 28 weeks. The blood levels of plasmalogens in patients with PD were compared with those of 39 age-matched normal controls. Results. Initial levels of plasma ethanolamine ether phospholipids in PD and ethanolamine plasmalogen of erythrocyte from PD were lower than those of age-matched normal controls. Oral administration of 1 mg/day of the purified ether phospholipids increased plasma ether phospholipids in PD and increased the relative composition of ether phospholipids of erythrocyte membrane in PD. The levels of ether phospholipids in peripheral blood reached to almost normal levels after 24 weeks. Furthermore, some clinical symptoms of PD improved concomitantly. Conclusion. 1 mg/day of oral administration of purified ether phospholipids derived from scallop can increase ether phospholipids in peripheral blood and concomitantly improve some clinical symptoms of PD. |
| format | Article |
| id | doaj-art-c4ccefc367664599a4b9f6b1edd7d3dc |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-c4ccefc367664599a4b9f6b1edd7d3dc2025-02-03T05:54:26ZengWileyParkinson's Disease2090-80832042-00802020-01-01202010.1155/2020/26710702671070Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary ReportShiro Mawatari0Shinji Ohara1Yoshihide Taniwaki2Yoshio Tsuboi3Toru Maruyama4Takehiko Fujino5Institute of Rheological Functions of Food, 2241-1 Kubara, Hisayama-cho, Kasuya-gun, Fukuoka 811-2501, JapanDepartment of Neurosurgery, Fukuoka Sanno Hospital, 3-6-45 Momochihama, Sawara-ku, Fukuoka 814-0001, JapanDepartment of Neurology, Fukuoka Sanno Hospital, 3-6-45 Momochihama, Sawara-ku, Fukuoka 814-0001, JapanDepartment of Neurology, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Johnan-ku, Fukuoka 814-0133, JapanDepartment of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, JapanBOOCS Clinic, 6F 6-18 Tenyamachi, Hakata-ku, Fukuoka 812-0025, JapanIntroduction. Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD). With the ageing of population, the frequency of PD is expected to increase dramatically in the coming decades. L-DOPA (1,3,4-dihydroxyalanine) is the most effective drug in the symptomatic treatment of PD. Nonmotor symptoms in PD include sleep problems, depression, and dementia, which are not adequately controlled with dopaminergic therapy. Here, we report the efficacy of oral administration of scallop-derived ether phospholipids to some nonmotor symptoms of PD. Methods. Ten (10) patients received oral administration of 1 mg/day of purified ether phospholipids derived from scallop for 24 weeks. Clinical symptoms and blood tests were checked at 0, 4, 12, 24, and 28 weeks. The blood levels of plasmalogens in patients with PD were compared with those of 39 age-matched normal controls. Results. Initial levels of plasma ethanolamine ether phospholipids in PD and ethanolamine plasmalogen of erythrocyte from PD were lower than those of age-matched normal controls. Oral administration of 1 mg/day of the purified ether phospholipids increased plasma ether phospholipids in PD and increased the relative composition of ether phospholipids of erythrocyte membrane in PD. The levels of ether phospholipids in peripheral blood reached to almost normal levels after 24 weeks. Furthermore, some clinical symptoms of PD improved concomitantly. Conclusion. 1 mg/day of oral administration of purified ether phospholipids derived from scallop can increase ether phospholipids in peripheral blood and concomitantly improve some clinical symptoms of PD.http://dx.doi.org/10.1155/2020/2671070 |
| spellingShingle | Shiro Mawatari Shinji Ohara Yoshihide Taniwaki Yoshio Tsuboi Toru Maruyama Takehiko Fujino Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report Parkinson's Disease |
| title | Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report |
| title_full | Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report |
| title_fullStr | Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report |
| title_full_unstemmed | Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report |
| title_short | Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report |
| title_sort | improvement of blood plasmalogens and clinical symptoms in parkinson s disease by oral administration of ether phospholipids a preliminary report |
| url | http://dx.doi.org/10.1155/2020/2671070 |
| work_keys_str_mv | AT shiromawatari improvementofbloodplasmalogensandclinicalsymptomsinparkinsonsdiseasebyoraladministrationofetherphospholipidsapreliminaryreport AT shinjiohara improvementofbloodplasmalogensandclinicalsymptomsinparkinsonsdiseasebyoraladministrationofetherphospholipidsapreliminaryreport AT yoshihidetaniwaki improvementofbloodplasmalogensandclinicalsymptomsinparkinsonsdiseasebyoraladministrationofetherphospholipidsapreliminaryreport AT yoshiotsuboi improvementofbloodplasmalogensandclinicalsymptomsinparkinsonsdiseasebyoraladministrationofetherphospholipidsapreliminaryreport AT torumaruyama improvementofbloodplasmalogensandclinicalsymptomsinparkinsonsdiseasebyoraladministrationofetherphospholipidsapreliminaryreport AT takehikofujino improvementofbloodplasmalogensandclinicalsymptomsinparkinsonsdiseasebyoraladministrationofetherphospholipidsapreliminaryreport |